Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
22.85
-0.56 (-2.39%)
Sep 2, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Revenue
Wuhan Hvsen Biotechnology had revenue of 406.71M CNY in the quarter ending June 30, 2026, a decrease of -3.88%. This brings the company's revenue in the last twelve months to 1.72B, up 8.68% year-over-year. In the year 2025, Wuhan Hvsen Biotechnology had annual revenue of 1.68B with 40.07% growth.
Revenue (ttm)
1.72B
Revenue Growth
+8.68%
P/S Ratio
2.72
Revenue / Employee
1.52M
Employees
1,133
Market Cap
4.69B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.68B | 480.92M | 40.07% |
| Dec 31, 2024 | 1.20B | 180.57M | 17.71% |
| Dec 31, 2023 | 1.02B | -3.14M | -0.31% |
| Jan 1, 2023 | 1.02B | 26.68M | 2.68% |
| Jan 1, 2022 | 996.22M | 218.76M | 28.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 3.00B |
| Shenzhen Weiguang Biological Products | 1.20B |
| ChemPartner PharmaTech | 1.16B |
| Boji Medical Technology | 961.34M |
| R&G PharmaStudies | 939.31M |
| Beijing Konruns Pharmaceutical | 917.05M |
| Beijing Bohui Innovation Biotechnology Group | 816.14M |
| Shanghai Obio Technology (Group) Corp. | 269.63M |